Carregant...
Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease
INTRODUCTION: Anti-integrin therapy for the treatment of patients with Crohn’s disease is rapidly evolving. Two agents, natalizumab and vedolizumab, are approved by the United States Food and Drug Administration for the treatment of Crohn’s disease, with vedolizumab the primary anti-integrin used du...
Guardat en:
| Publicat a: | Expert Opin Investig Drugs |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4926164/ https://ncbi.nlm.nih.gov/pubmed/26822204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543784.2016.1148137 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|